Adult Patient Preferences for Long-Acting ADHD Treatments: A Discrete Choice Experiment

References

• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. 2013.
   Google Scholar
• Fayyad J, Sampson NA, Hwang I, et al. The descriptive epidemiology of DSM-IV adult ADHD in the World Health Organization world mental health surveys. Atten Defic Hyperact Disord. 2017;9(1):47–65. doi:10.1007/s12402-016-0208-3
   PubMedGoogle Scholar
• Kooij SJ, Bejerot S, Blackwell A, et al. European consensus statement on diagnosis and treatment of adult ADHD: the European network adult ADHD. BMC Psychiatry. 2010;10(1):67. doi:10.1186/1471-244X-10-67
   PubMed Web of Science ®Google Scholar
• Geffen J, Forster K. Treatment of adult ADHD: a clinical perspective. Ther Adv Psychopharmacol. 2018;8(1):25–32. doi:10.1177/2045125317734977
   PubMed Web of Science ®Google Scholar
• De Crescenzo F, Cortese S, Adamo N, Janiri L. Pharmacological and non-pharmacological treatment of adults with ADHD: a meta-review. Evid Based Ment Health. 2017;20(1):4–11. doi:10.1136/eb-2016-102415
   PubMed Web of Science ®Google Scholar
• Briars L, Todd T. A review of pharmacological management of attention-deficit/hyperactivity disorder. J Pediatr Pharmacol Ther. 2016;21(3):192–206. doi:10.4172/2327-5146.1000313
   Google Scholar
• Greenhill LL, Pliszka S, Dulcan MK, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2002;41(2Suppl):26S–49S. doi:10.1097/00004583-200202001-00003
   Google Scholar
• CADDRA. Canadian ADHD resource alliance (CADDRA): Canadian ADHD practice guidelines; 2020. Available from: https://www.caddra.ca/wp-content/uploads/CADDRA-Guidelines-4th-Edition_-Feb2018.pdf. Accessed July 19, 2020.
   Google Scholar
• NICE. Attention deficit hyperactivity disorder: diagnosis and management NICE guidelines [CG72]; 2018. Available from: https://www.nice.org.uk/guidance/ng87. Accessed July 19, 2020.
   Google Scholar
• Weisler RH. Review of long-acting stimulants in the treatment of attention deficit hyperactivity disorder. Expert Opin Pharmacother. 2007;8(6):745–758. doi:10.1517/14656566.8.6.745
   PubMed Web of Science ®Google Scholar
• López FA, Leroux JR. Long-acting stimulants for treatment of attention-deficit/hyperactivity disorder: a focus on extended-release formulations and the prodrug lisdexamfetamine dimesylate to address continuing clinical challenges. Atten Defic Hyperact Disord. 2013;5(3):249–265. doi:10.1007/s12402-013-0106-x
   PubMedGoogle Scholar
• Austerman J. ADHD and behavioral disorders: assessment, management, and an update from DSM-5. Cleve Clin J Med. 2015;82(suppl1):S2–S7. doi:10.3949/ccjm.82.s1.01
   Web of Science ®Google Scholar
• Mattingly GW, Wilson J, Rostain AL. A clinician’s guide to ADHD treatment options. Postgrad Med. 2017;129(7):657–666. doi:10.1080/00325481.2017.1354648
   PubMed Web of Science ®Google Scholar
• Brinkman WB, Epstein JN. Treatment planning for children with attention-deficit/hyperactivity disorder: treatment utilization and family preferences. Patient Prefer Adherence. 2011;5:45–56. doi:10.2147/PPA.S10647
   Web of Science ®Google Scholar
• Schatz NK, Fabiano GA, Cunningham CE, et al. Systematic review of patients’ and parents’ preferences for ADHD treatment options and processes of care. Patient. 2015;8(6):483–497. doi:10.1007/s40271-015-0112-5
   Google Scholar
• Ng X, Bridges JFP, Ross MM, et al. A latent class analysis to identify variation in caregivers’ preferences for their child’s attention-deficit/hyperactivity disorder treatment: do stated preferences match current treatment? Patient. 2017;10(2):251–262. doi:10.1007/s40271-016-0202-z
   Google Scholar
• Van Brunt K, Matza LS, Classi PM, Johnston JA. Preferences related to attention-deficit/hyperactivity disorder and its treatment. Patient Prefer Adherence. 2011;5:33–43. doi:10.2147/PPA.S6389
   PubMed Web of Science ®Google Scholar
• DosReis S, Park A, Ng X, et al. Caregiver treatment preferences for children with a new versus existing attention-deficit/hyperactivity disorder diagnosis. J Child Adolesc Psychopharmacol. 2017;27(3):234–242. doi:10.1089/cap.2016.0157
   Web of Science ®Google Scholar
• Lloyd A, Hodgkins P, Dewilde S, Sasané R, Falconer S, Sonuga Barke E. Methylphenidate delivery mechanisms for the treatment of children with attention deficit hyperactivity disorder: heterogeneity in parent preferences. Int J Technol Assess Health Care. 2011;27(3):215–223. doi:10.1017/S0266462311000249
   Web of Science ®Google Scholar
• Nafees B, Setyawan J, Lloyd A, et al. Parent preferences regarding stimulant therapies for ADHD: a comparison across six European countries. Eur Child Adolesc Psychiatry. 2014;23(12):1189–1200. doi:10.1007/s00787-013-0515-6
   PubMed Web of Science ®Google Scholar
• Glenngård AH, Hjelmgren J, Thomsen PH, Tvedten T. Patient preferences and willingness-to-pay for ADHD treatment with stimulants using discrete choice experiment (DCE) in Sweden, Denmark and Norway. Nord J Psychiatry. 2013;67(5):351–359. doi:10.3109/08039488.2012.748825
   PubMed Web of Science ®Google Scholar
• dosReis S, Ng X, Frosch E, Reeves G, Cunningham C, Bridges JFP. Using best–worst scaling to measure caregiver preferences for managing their child’s ADHD: a Pilot Study. Patient. 2015;8(5):423–431. doi:10.1007/s40271-014-0098-4
   PubMedGoogle Scholar
• Matza LS, Secnik K, Rentz AM, et al. Assessment of health state utilities for attention-deficit/hyperactivity disorder in children using parent proxy report. Qual Life Res. 2005;14(3):735–747. doi:10.1007/pl00022070
   PubMed Web of Science ®Google Scholar
• Ross M, Bridges JFP, Ng X, et al. A best-worst scaling experiment to prioritize caregiver concerns about ADHD medication for children. Psychiatr Serv. 2015;66(2):208–211. doi:10.1176/appi.ps.201300525
   PubMed Web of Science ®Google Scholar
• Waschbusch DA, Cunningham CE, Pelham WE, et al. A discrete choice conjoint experiment to evaluate parent preferences for treatment of young, medication naive children with ADHD. J Clin Child Adolesc Psychol. 2011;40(4):546–561. doi:10.1080/15374416.2011.581617
   PubMed Web of Science ®Google Scholar
• Bridges JFP, Hauber AB, Marshall D, et al. Conjoint analysis applications in health—a checklist: a report of the ISPOR good research practices for conjoint analysis task force. Value Health. 2011;14(4):403–413. doi:10.1016/j.jval.2010.11.013
   PubMed Web of Science ®Google Scholar
• Johnson FR, Lancsar E, Marshall D, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR conjoint analysis experimental design good research practices task force. Value Health. 2013;16(1):3–13. doi:10.1016/j.jval.2012.08.2223
   PubMed Web of Science ®Google Scholar
• Erensen JG, Beusterien K, Cambron-Mellott MJ, Hallissey B, Matos J, Mikl J. Unlocking patient preferences for long-acting treatments for ADHD: results of a discrete choice experiment. In: American Professional Society of ADHD and Related Disorders. 2020.
   Google Scholar
• Purdue Pharmaceuticals. Adhansia XR: highlights of prescribing information; 2019. Available from: https://app.adlontherapeutics.com/adhansia-xr/fpi.pdf. Accessed April 3, 2019.
   Google Scholar
• Shire US Inc. ADDERALL XR®: highlights of prescribing information; 2013. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf. Accessed November 20, 2018.
   Google Scholar
• Novartis Pharmaceuticals Corporation. FOCALIN XR: highlights of prescribing information; 2019. Available from: https://www.novartis.us/sites/www.novartis.us/files/focalinXR.pdf. Accessed April 8, 2019.
   Google Scholar
• UCB. Metadate CD: highlights of prescribing information; 2013. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021259s023lbl.pdf. Accessed April 9, 2019.
   Google Scholar
• Caballero J, Darsey EH, Walters F, Belden HW. Methylphenidate extended-release oral suspension for the treatment of attention-deficit/hyperactivity disorder: a practical guide for pharmacists. Integr Pharm Res Pract. 2017;6:163. doi:10.2147/IPRP.S142576
   Web of Science ®Google Scholar
• Carlson G, Kelly K. Stimulant rebound: how common is it and what does it mean? J Child Adolesc Psychopharmacol. 2003;13(2):137–142. doi:10.1089/104454603322163853
   PubMed Web of Science ®Google Scholar
• Childress AC, Wigal SB, Brams MN, et al. Efficacy and safety of amphetamine extended-release oral suspension in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2018;28(5):306–313. doi:10.1089/cap.2017.0095
   PubMed Web of Science ®Google Scholar
• Ginsberg Y, Arngrim T, Philipsen A, et al. Long-term (1 year) safety and efficacy of methylphenidate modified-release long-acting formulation (MPH-LA) in adults with attention-deficit hyperactivity disorder: a 26-week, flexible-dose, open-label extension to a 40-week, double-blind, randomised, placebo-controlled core study. CNS Drugs. 2014;28(10):951. doi:10.1007/S40263-014-0180-4
   Web of Science ®Google Scholar
• Huss M, Ginsberg Y, Tvedten T, et al. Methylphenidate hydrochloride modified-release in adults with attention deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial. Adv Ther. 2014;31(1):44–65. doi:10.1007/s12325-013-0085-5
   Web of Science ®Google Scholar
• Kolar D, Keller A, Golfinopoulos M, Cumyn L, Syer C, Hechtman L. Treatment of adults with attention-deficit/hyperactivity disorder. Neuropsychiatr Dis Treat. 2008;4(2):389–403. doi:10.2147/ndt.s6985
   PubMedGoogle Scholar
• López FA, Childress A, Adeyi B, et al. ADHD symptom rebound and emotional lability with lisdexamfetamine dimesylate in children aged 6 to 12 years. J Atten Disord. 2017;21(1):52–61. doi:10.1177/1087054712474685
   Web of Science ®Google Scholar
• Stark JG, Engelking D, McMahen R, Sikes C. A randomized crossover study to assess the pharmacokinetics of a novel amphetamine extended-release orally disintegrating tablet in healthy adults. Postgrad Med. 2016;128(7):648–655. doi:10.1080/00325481.2016.1216716
   PubMed Web of Science ®Google Scholar
• Shire US Inc. MYDAYIS: highlights of prescribing information; 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022063s000lbl.pdf. Accessed May 4, 2021.
   Google Scholar
• Swanson JM, Wigal SB, Wigal T, et al. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics. 2004;113(3 Pt 1):e206–16. doi:10.1542/peds.113.3.e206
   PubMed Web of Science ®Google Scholar
• Weisler RH. Safety, efficacy and extended duration of action of mixed amphetamine salts extended-release capsules for the treatment of ADHD. Expert Opin Pharmacother. 2005;6(6):1003–1017. doi:10.1517/14656566.6.6.1003
   PubMed Web of Science ®Google Scholar
• Weisler RH, Childress AC. Treating attention-deficit/hyperactivity disorder in adults: focus on once-daily medications. Prim Care Companion CNS Disord. 2011;13:6. doi:10.4088/PCC.11r01168
   Google Scholar
• Wigal T, Brams M, Frick G, Yan B, Madhoo M. A randomized, double-blind study of SHP465 mixed amphetamine salts extended-release in adults with ADHD using a simulated adult workplace design. Postgrad Med. 2018;130(5):481–493. doi:10.1080/00325481.2018.1481712
   PubMed Web of Science ®Google Scholar
• Wigal SB, Childress A, Berry SA, et al. Efficacy and safety of a chewable methylphenidate extended-release tablet in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2017;27(8):690. doi:10.1089/CAP.2016.0177
   PubMed Web of Science ®Google Scholar
• Wigal SB, Childress AC, Belden HW, Berry SA. NWP06, an extended-release oral suspension of methylphenidate, improved attention-deficit/hyperactivity disorder symptoms compared with placebo in a laboratory classroom study. J Child Adolesc Psychopharmacol. 2013;23(1):3–10. doi:10.1089/cap.2012.0073
   PubMed Web of Science ®Google Scholar
• Wigal SB, Wigal T, Childress A, Donnelly GAE, Reiz JL. The time course of effect of multilayer-release methylphenidate hydrochloride capsules. J Atten Disord. 2016;24(3):108705471667233. doi:10.1177/1087054716672335
   Web of Science ®Google Scholar
• Wigal T, Brams M, Gasior M, Gao J, Squires L, Giblin J. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design. Behav Brain Funct. 2010;6(1):34. doi:10.1186/1744-9081-6-34
   PubMed Web of Science ®Google Scholar
• Shire US Inc. VYVANSE ®: highlights of prescribing information; 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208510lbl.pdf. Accessed November 20, 2018.
   Google Scholar
• Tris Pharma. QUILLICHEW ER®: highlights of prescribing information; 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207960s005lbl.pdf. Accessed April 9, 2019.
   Google Scholar
• Tris Pharma. QUILLIVANT XR®: highlights of prescribing information; 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202100s012lbl.pdf. Accessed April 9, 2019.
   Google Scholar
• Novartis Pharmaceuticals Corporation. Ritalin LA®: highlights of prescribing information; 2019. Available from: https://www.novartis.us/sites/www.novartis.us/files/ritalinLA_pmg.pdf. Accessed November 20, 2018.
   Google Scholar
• Neos Therapeutics. ADZENYS XR-ODT: highlights of prescribing information; 2016. Available from: http://www.neostxcontent.com/Labeling/Adzenys/Adzenys_PI.pdf. Accessed April 9, 2019.
   Google Scholar
• Rhodes Pharmaceuticals. APTENSIO XR: highlights of prescribing information; 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205831s003lbl.pdf. Accessed April 8, 2019.
   Google Scholar
• Janssen Pharmaceuticals. CONCERTA®: highlights of prescribing information; 2013. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021121s038lbl.pdf. Accessed November 20, 2018.
   Google Scholar
• Tris Pharma. DYANAVEL XR: highlights of prescribing information; 2019. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208147s002lbl.pdf. Accessed April 9, 2019.
   Google Scholar
• Adler LA, Spencer T, Faraone SV, et al. Validity of pilot adult ADHD self- report scale (ASRS) to rate adult ADHD symptoms. Ann Clin Psychiatry. 2006;18(3):145–148. doi:10.1080/10401230600801077
   PubMedGoogle Scholar
• Kessler RC, Adler L, Ames M, et al. The World Health Organization adult ADHD self-report scale (ASRS): a short screening scale for use in the general population. Psychol Med. 2005;35(2):245–256. doi:10.1017/S0033291704002892
   PubMed Web of Science ®Google Scholar
• Office of Management and Budget. Standard occupational classification manual; 2018. Available from: https://www.bls.gov/soc/2018/soc_2018_manual.pdf. Accessed April 13, 2021.
   Google Scholar
• Johnston RJ, Boyle KJ, Vic Adamowicz W, et al. Contemporary guidance for stated preference studies. J Assoc Environ Resour Econ. 2017;4(2):319–405. doi:10.1086/691697
   Web of Science ®Google Scholar
• Hauber AB, González JM, Groothuis-Oudshoorn CGM, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR conjoint analysis good research practices task force. Value Health. 2016;19(4):300–315. doi:10.1016/j.jval.2016.04.004
   PubMed Web of Science ®Google Scholar
• Dziak JJ, Coffman DL, Lanza ST, Li R. Sensitivity and specificity of information criteria. PeerJ. 2015;3:e1350. doi:10.7287/peerj.preprints.1103v3
   Google Scholar
• American Psychological Association Presidential Task Force on Evidence-Based Practice. Evidence-based practice in psychology. Am Psychol. 2006;61(4):271–285. doi:10.1037/0003-066X.61.4.271
   PubMed Web of Science ®Google Scholar
• Institute of Medicine. Crossing the Quality Chasm: A New Health System for the 21st Century. National Academies Press; 2001.
   Google Scholar
• Mattingly GW, Anderson RH. Optimizing outcomes in ADHD treatment: from clinical targets to novel delivery systems. CNS Spectr. 2016;21(S1):48–58. doi:10.1017/S1092852916000808
   Web of Science ®Google Scholar
• Mattingly GW, Jain R, Hegarty J, O’Brien Q. Investigation of clinical practice challenges in the management of ADHD. In: American Professional Society of ADHD & Related Disorders Annual Meeting; 2018.
   Google Scholar
• Childress AC, Kollins SH, Cutler AJ, Marraffino A, Sikes CR. Efficacy, safety, and tolerability of an extended-release orally disintegrating methylphenidate tablet in children 6–12 years of age with attention-deficit/hyperactivity disorder in the laboratory classroom setting. J Child Adolesc Psychopharmacol. 2017;27(1):66–74. doi:10.1089/cap.2016.0002
   PubMed Web of Science ®Google Scholar
• Smith G. Does gender influence online survey participation?: a record-linkage analysis of university faculty online survey response behavior; 2008. Available from: https://scholarworks.sjsu.edu/elementary_ed_pub. Accessed April 12, 2021.
   Google Scholar
• Keusch F. Why do people participate in web surveys? Applying survey participation theory to Internet survey data collection. Manag Rev Q. 2015;65(3):183–216. doi:10.1007/s11301-014-0111-y
   Google Scholar
• Lee SI, Song D-H, Shin DW, et al. Efficacy and safety of atomoxetine hydrochloride in Korean adults with attention-deficit hyperactivity disorder. Asia Pac Psychiatry. 2014;6(4):386–396. doi:10.1111/appy.12160
   Web of Science ®Google Scholar
• Biederman J, Faraone SV, Monuteaux MC, Bober M, Cadogen E. Gender effects on attention-deficit/hyperactivity disorder in adults, revisited. Biol Psychiatry. 2004;55(7):692–700. doi:10.1016/j.biopsych.2003.12.003
   PubMed Web of Science ®Google Scholar